affirm narrow-moat rate baxter freseniu
updat forecast estim may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim may
price data jun
rate updat jun
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
follow spin-off baxalta baxter new
manag team focus increas effici
innov medic product focu result much
improv profit cash flow gener sinc go
forward compani aim roughli organ sale growth
primarili new product geograph launch
double-digit adjust earn per share free cash flow growth
compound annual acquisit could add
prospect
baxter renal acut care technolog support patient
fail organ often kidney segment
compani gener revenu at-hom patient
use periton dialysi pd equip solut
howev also sell hemodialysi product dialysi clinic
continu renal replac therapi crrt organ
support equip intens care unit new renal segment
launch includ kaguya under-penetrated pd market
japan hdx enabl theranova mimic kidney function
close point care pd system greatli reduc solut
ship month acut care baxter plan launch product
like prismax simplifi burden deliv crrt
baxter pursu ambiti growth strategi roughli doubl
number molecul sell varieti deliveri
wound closur bleed control product new launch
faster prep version flagship hemostat floseal could
help clinician save signific time oper room
medic deliveri nutrit manag need turn
around oper recent hurrican regulatori
concern damag baxter reput reliabl supplier
critic therapi effort may take time new
segment return growth
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
busi segment renal segment sale includ
periton dialysi hemodialysi product chronic ill patient
acut therapi segment offer kidney organ support
tool intens care situat medic deliveri segment
sale sell iv pump administr set solut nutrit
sale offer parenter nutrit therapi
pharmaceut segment sale offer inject drug
anesthet gase compound servic advanc surgeri
segment sale provid hemostast product biosurg
sealant contract manufactur round remain sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
affirm narrow-moat rate baxter
take fresh look dialysi inject therapy-
focus baxter freseniu se maintain
narrow moat stabl trend rate firm
also rais fair valu estim account cash
flow gener sinc previou updat adjust
underli project baxter rais fair
valu estim per share time
updat earn per share previous
freseniu increas fair valu estim
local share eur per share time updat
earn eur per share previous
believ narrow moat surround organ
howev moat sourc differ due way
firm tackl target market exampl baxter
focu medic technolog includ at-hom periton
dialysi product infus pump advanc
deliveri system keep primari moat sourc
switch cost intang asset freseniu se
benefit element particularli
inject therapi kabi segment promin
enough off-set concentr servic particularli
in-clin dialysi contribut primarili cost
advantag opinion
rais fair valu estim baxter per
share primarili reflect cash flow gener
sinc last updat oper assumpt remain
larg unchang expect baxter
revenu grow compound annual includ
currenc headwind cut basi point
oper growth rate next five year
segment expect renal care grow compound
annual next five year primarili reflect
compound annual growth baxter medic deliveri
segment success expect infus pump launch
help baxter get back normal growth pattern
beyond recent iv solut headwind
pharmaceut estim baxter ambiti growth
plan lead compound annual growth around
consid on-going headwind may
difficult overcom estim nutrit
segment grow compound annual
next five year new product launch continu
domin respect nich expect acut
therapi advanc surgeri segment grow
compound annual
valuat perspect freseniu stock appear
better valu baxter stock current see
upsid freseniu stock appear bit
depress roughli flat bottom-lin prospect
relat on-going invest challeng
us market possibl anticip
continu significantli outpac expect long
run done sinc baxalta split
possibl think oper goal ambiti
mere meet goal stock may revert toward
fair valu estim
hit adjust oper margin
assum baxter reach low
end manag target rang margin
expans come continu sg cost
control gross margin expans mix benefit
manufactur effici improv profit
effici capit expenditur plan help baxter
gener billion free cash flow
billion use weight averag cost capit
around discount assumpt assum
lower-cost debt becom slightli preval part
capit structur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
bear-cas scenario valu baxter per share
scenario assum new product launch
lacklust headwind iv solut nutrit
continu keep sale growth next
five year versu expect base case also
forecast gross margin
improv
materi expect firm adjust oper
margin rise well
target free cash flow reach billion
well
baxter dug narrow moat around provid dialysi
inject therapi complex deliveri system
baxter claim top-tier posit product
line typic compet concentr group
peer overal think would difficult new firm
enter nich primarili due switch cost
associ medic equip
intang asset surround proprietari technolog
manufactur process factor form basi
baxter moat gener see long runway
baxter gener econom profit exist
technolog innov pipelin new product
current baxter gener roic mid-teen
well excess capit cost firm introduc
new technolog aim becom even effici
believ margin could improv bolster
confid baxter abil gener econom
profit long run
renal care segment sale believ
baxter benefit primarili switch cost relat
place equip intang asset associ
proprietari technolog baxter second largest provid
dialysi equip relat consum behind
freseniu medic organ offer
broad spectrum dialysi product strength larg
presenc rel stabl healthcar market
give compani medium uncertainti rate
bull-cas scenario valu baxter per share
scenario assum new product launch
favor price condit greater market penetr
boost growth next five year
base case scenario see potenti
variabl base case forecast nutrit
segment higher-growth acut therapi
advanc surgeri segment although segment
contribut higher growth rate bull scenario
also forecast manag exceed initi
cost-sav estim streamlin manufactur
distribut effort success transit
growth factor push adjust oper margin
slightli high end target
rang free cash flow rise billion
scenario well
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
lie separ technolog geograph footprint
periton dialysi pd product baxter thrive
home set strong presenc emerg
market baxter domin pd medic product market
market share around versu freseniu
patient share altern freseniu lead way
hemodialysi hd technolog use
clinic hd patient share versu baxter
around share pd equip place baxter
structur payment use equip relat
consum monthli subscript
consum tube solut deliv directli
patient baxter logist network
opinion treatment work patient littl
incent switch due inertia factor surround
train around self-administ treatment
compani busi model creat recur
revenu stream consum place equip
baxter proprietari medic technolog pd abil
continu innov creat moat sourc relat
intang asset baxter pd offer current
benefit differenti cycler
sharesourc technolog commun patient result
doctor allow doctor adjust treatment
remot particularli valuabl rural
emerg market factor current set
baxter tool apart competit pd offer abil
innov remain core intang asset moat sourc
case medic technolog compani
pipelin initi includ point care pd system
greatli reduc solut ship month
current weigh pound hdx dialyz
enabl theranova close mimic kidney
function aim reduc cardiovascular side
effect often associ hemodialysi
similar dynam renal care busi exist baxter
acut therapi segment sale sell organ
support tool intens care unit hospit baxter
clearli lead continu renal replac therapi
crrt busi believ moat acut therapi stem
primarili switch cost relat caregiv train
intang asset similar renal care segment
rel small percentag baxter total sale
estim midsingl digit percentag sale
baxter
sustain competit advantag recur revenu
outsid renal care infus pump medic
technolog help hospit staff primarili nurs
automat administ medic therapi often lead
recur consum sale administr set iv
solut inject therapi infus pump
rel long life seven year give
long period enjoy recur consum sale
pump place pump offer network
softwar help devic becom embed
workflow caregiv
replac cycl hospit often stick familiar
technolog ensur smooth therapi administr
caregiv well overal infus pump place
hospit believ facil unlik creat
workflow disrupt switch new pump provid
devic often consid gpo contract
negoti on-going sale administr set
therapeut solut although altern deliveri
method util inject therapi -- iv
solut sale nutrit sale
pharmaceut estim sale -- could
infus pump repres key recur
revenu associ infus pump technolog
intang asset front technic featur infus
pump relat consum posit neg
affect caregiv workload patient experi
baxter proprietari technolog remain top-tier
posit concentr market second largest
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
provid also baxter innov pipelin
appear full four new infus pump expect
launch includ new pump platform
includ option larg volum pump syring
administr patient-control analgesia one
pump put baxter par pump
market leader overal infus
pump busi appear add baxter switch cost
intang asset moat sourc rel
concentr market includ former hospira
oper freseniu braun
carefus acquisit
part consum stori infus
pump believ baxter therapeut offer
estim sale -- iv solut estim
baxter sale nutrit sale gener
pharmaceut sale -- contain element
scale-rel advantag intang asset well
although consid cost advantag primari
moat sourc baxter overal baxter enjoy top
posit iv solut stand lead posit
parenter nutrit excel difficult manufactur
gener pharmaceut anesthesia asept
premix baxter typic face limit competit
target market top-tier competitor market
includ freseniu braun former hospira asset
overal see signific
barrier entri around busi keep
inject market baxter particip quit
concentr competit perspect specif
key peer estim would take
million three year build manufactur facil
would allow new entrant gain enough scale
compet effect iv solut busi
 iv solut market serv primarili three
provid baxter icu medic freseniu se
similarli
larg
invest would requir nutrit
gener pharmaceut busi beyond up-front
cost on-going cost associ ensur
complianc due stringent regulatori standard remain
high factor contribut signific entri barrier
new competitor highlight recent
shortag iv solut nutrit market
share shift occur primarili exist
player rather invit signific new competit
beyond scale requir compet success iv
solut nutrit pharmaceut busi see
intang asset relat primarili
provid mix benefit reput
requir consid long-term supplier
hospit nich even gener pharmaceut
baxter primarili particip market complex
manufactur administr requir
inhal anesthet inject therapi franchis
baxter typic face competit
competitor primarili due manufactur complex
much higher oral gener exampl
competit price pressur pervas
beyond gener manufactur requir baxter
also excel asept premix product manufactur
requir keep molecul stabl help ensur
safeti product administr offer ready-to-us
inject care set improv patient safeti
reduc time associ administr task
creat valuabl tool nurs doctor
front line care help baxter gener mix
benefit otherwis commodifi market
nutrit product baxter benefit intang
differenti formul deliveri system ad
intang asset see reputational-rel
therapeut offer well
particularli around abil reliabl supplier
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ramp invest new molecul gain scale
put level play field larger peer
view posit moat busi
neg iv nutrit solut baxter recent
suffer reput setback hurrican activ
knock manufactur capac
essenti therapi despit longer suppli
constrain baxter still experienc revenu declin
busi hospit custom continu
use supplier lower-pr administr method
requir baxter shortag period baxter
reput reliabl supplier critic therapi
appear weaken may take time
chang reput hospit protocol wake
recent shortag period overal though view
posit trend pharmaceut neg trend
iv nutrit solut larg offset
essenti therapi hospit gpo negoti
advanc surgeri sale think firm benefit
primarili intang asset proprietari
product control bleed close wound
surgic procedur baxter occupi second posit
market behind johnson johnson
advanc hemostat sealant flagship tisseel
floseal product remain differenti baxter continu
innov area new launch aim
includ reduc prepar time floseal reduc
sutur time coupler product on-going
innov add sustain segment
baxter segment sale consist primarili
contract manufactur pharmaceut compani
contribut baxter scale howev
view contract manufactur advantag busi
baxter moat trend appear stabl
busi compani face competit limit
number peer due difficulti compet
medic product switch cost medic
equip scale requir intang asset
target market gener view baxter compet
innov new product launch across busi line
help baxter broaden market offer remain
top-tier competitor obtain mix-rel benefit
factor give us larg stabl view trend
busi despit price constraint common
healthcar industri posit one
price-sensit busi pharmaceut baxter
evolv primarili
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
obaxt new manag team reve
growth engin addit evolutionari
goal major busi line pipelin
includ sever long-term wildcard stock
potenti treat blood-bas cancer
filtrat technolog
oemerg market sale prime
sourc growth mani baxter product
especi periton dialysi nutrit solut
oth compani continu strive even higher
profit keep earn growth
sale growth forese futur
oalthough baxter product essenti medic
care patient health mani similar
altern limit baxter price power
owhil pull trigger larg deal yet
baxter new manag team shown
appetit acquisit add uncertainti
prospect could reduc balanc sheet
obaxt reput reliabl supplier iv
solut nutrit relat market share may
easi recov recent shortag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
baxter continu oper net leverag significantli
time target net leverag
manag debt come due next five year
fulli cover exist cash also on-going free cash flow
billion manag expect grow
billion billion appear
strong give baxter plenti financi flexibl
substanti financi resourc dispos
firm oper net leverag target think
baxter capac consid capital-alloc
activ caus net leverag rise recent level
exampl manag highlight appetit
acquisit also baxter could return cash
sharehold compani made billion dividend
payment aim return
adjust net incom sharehold go forward
repurchas billion share baxter
repurchas anoth billion first quarter
author repurchas billion march
presenc rel stabl healthcar market
give compani medium uncertainti rate think
baxter shed riskier asset baxalta spin-off
leav well-diversifi compani particip
market limit risk signific disrupt howev
baxter product line particularli iv solut
nutrit product gener inject
commodifi new competitor decid make
substanti invest need enter market
think price pressur manag
volum increas mix benefit differenti
must innov maintain competit advantag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
compani
particularli renal care infus pump acut therapi
appropri product set peer may surpass
baxter technolog enough affect market share
eventu baxter appetit acquisit also appear
increas creat uncertainti around
trajectori could add financi leverag
balanc sheet factor could add risk
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ceo/chairman board/
repres date owner name posit common share held report holder issuer
america corpor
fidel manag research compani
share
fund
share
fund
current assign baxter standard stewardship
rate recogn signific out-performance
new manag team deliv sharehold sinc
take split baxalta gener
think baxter asset neglect bit
previou organiz structur busi
qualiti still remain high due inher competit
advantag new manag team strategi
refresh profit
perspect remain baxter busi
split jose almeida previous
chairman ceo covidien prior acquisit
replac longtim baxter chairman ceo
robert parkinson jr sinc join baxter almeida
team focus improv profit cash
flow margin risen substanti baxter
current busi
larg overshadow
higher-growth higher-margin baxalta asset prior
split pleas manag team
abl boost profit line med-tech industri
standard short period time would also note
almeida appear rev previous
rel dormant innov engin bode well
futur growth prospect
although view chang posit signific
uncertainti surround new team capit alloc
polici specif remain concern potenti
acquisit could eras profit gain
manag made past year would
also note team shi repurchas
share recent quarter gener glad see
manag attempt purchas share attract
valuat remain seen team maintain
disciplin face share appreci sinc earli
push stock fair valu
opinion sharehold also awar financi
flexibl could declin pull trigger larg
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
acquisit current believ baxter capac
consid activ increas net leverag
would want see firm add much leverag beyond
net leverag target time sustain period
given innov regulatori risk associ
target market strong growth prospect
surpris baxter current dividend pay-out ratio
remain target around adjust net
incom growth prospect slow increas
pay-out ratio could add sharehold return go forward
well
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
affirm narrow-moat rate baxter
take fresh look dialysi inject therapy-
focus baxter freseniu se maintain
narrow moat stabl trend rate firm
also rais fair valu estim account cash
flow gener sinc previou updat adjust
underli project baxter rais fair
valu estim per share time
updat earn per share previous
freseniu increas fair valu estim
local share eur per share time updat
earn eur per share previous
believ narrow moat surround organ
howev moat sourc differ due way
firm tackl target market exampl baxter
focu medic technolog includ at-hom periton
dialysi product infus pump advanc
deliveri system keep primari moat sourc
switch cost intang asset freseniu se
benefit element particularli
inject therapi kabi segment promin
enough off-set concentr servic particularli
in-clin dialysi contribut primarili cost
advantag opinion
valuat perspect freseniu stock appear
better valu baxter stock current see
upsid freseniu stock appear bit
depress roughli flat bottom-lin prospect
relat on-going invest challeng
us market possibl anticip
continu significantli outpac expect long
run done sinc baxalta split
possibl think oper goal ambiti
mere meet goal stock may revert toward
fair valu estim
continu baxter review transfer
coverag new analyst expect publish new fair
valu estim later may
place baxter review transfer coverag
new analyst expect publish new fair valu
estim second quarter
baxter report solid outlook match
constant-curr growth adjust
oper margin basi point last
year fourth quarter baxter end fiscal
slightli ahead expect compani
outlook constant-curr revenu growth
adjust oper margin fall near
forecast therefor dont anticip major chang
fair valu estim updat model
baxter still linger issu deal
clari warn
letter on-going pressur
cyclophosphamid still encourag underli
perform busi new product innov
remain headwind pharmaceut divis
expect mid-single-digit growth baxter
segment leav narrow moat rate
baxter clinic nutrit medic deliveri
segment fell slightli forecast fourth
quarter strong result pharmaceut advanc
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
surgeri segment kept overal growth larg step
expect clinic nutrit medic
deliveri segment neg flat constant-
currenc sale respect continu face linger
effect note previou quarter suppli disrupt
relat hurrican maria expect perform
gradual improv segment especi
compani face easier year-over-year comparison
manag also note longer sale cycl infus
pump custom delay purchas even though baxter
believ gain increment share
baxter segment sale better expect
pharmaceut segment growth benefit new
product launch healthi demand anesthesia
compound servic anticip competit
cyclophosphamid brevibloc sale
million respect quarter like make
quarter segment growth difficult sustain
temporari benefit competitor suppli constraint help
boost growth recothrom lead growth
advanc surgeri lastli renal segment sale growth
match expect manag note high-
single-digit pd growth unit state off-set
declin sale less profit blood line product
result baxter focu profit busi
rule unconstitut district court
near-term impact fundament dec
dec judg reed connor northern district
texa issu rule effect declar patient
protect afford act
unconstitut assum littl chang
compani cover healthcar sector
near term rule like make way
appeal process surpris see
case third appear make front
 suprem court potenti timelin final
basi decis find root congress
elimin shared-respons financi penalti
accompani passag tax cut job act
late last year short judg connor found individu
mandat essenti insever provis
congress decis elimin enforc
tax penalti law render entireti
legisl unconstitut logic follow
 suprem court decis upheld
constitut congress power taxat
view healthcar provid sector at-risk
stem chang prevail healthcar
legisl whether chang individu coverag
roll-back medicaid expans higher uninsur
rate unequivoc equat pressur hospit margin
payer perspect trade-off littl less clear
although medicaid-focus insur like feel
bulk enrol loss
intend make chang moat rate fair
valu estim result decis continu
monitor case make way appel
court come month outcom timelin
uncertain make meaning chang
assumpt earli day addit wildcard
potenti legisl action muddi
ultim financi penalti carri
insur coverag set end jan
understand feder govern intend
maintain statu quo appeal process
insur alreadi lock rate propos
earliest like see potenti effect
rule premium polici offer slate
open enrol season
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
